Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy.

MLA

Wu, Xin, et al. “Unveiling the PDK4-Centered Rituximab-Resistant Mechanism in DLBCL: The Potential of the ‘Smart’ Exosome Nanoparticle Therapy.” Molecular Cancer, vol. 23, no. 1, July 2024, pp. 1–25. EBSCOhost, https://doi.org/10.1186/s12943-024-02057-0.

APA

Wu, X., Ban, C., Deng, W., Bao, X., Tang, N., Wu, Y., Deng, Z., Xiong, J., & Zhao, Q. (2024). Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the “Smart” exosome nanoparticle therapy. Molecular Cancer, 23(1), 1–25. https://doi.org/10.1186/s12943-024-02057-0

Chicago

Wu, Xin, Chunmei Ban, Woding Deng, Xuewei Bao, Ning Tang, Yupeng Wu, Zhixuan Deng, Jianbin Xiong, and Qiangqiang Zhao. 2024. “Unveiling the PDK4-Centered Rituximab-Resistant Mechanism in DLBCL: The Potential of the ‘Smart’ Exosome Nanoparticle Therapy.” Molecular Cancer 23 (1): 1–25. doi:10.1186/s12943-024-02057-0.